Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis.

Iguratimod () is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of act on SLE.

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.

Patients with rheumatic diseases (RD) are considered to be a high-risk population for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The effectiveness of inactivated COVID-19 vaccinations (ICVs) was described as more effective than 95%. Despite this, no data on the immunogenicity and safety of the ICV in Han race stable RD patients in China.